Dataset Information
Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.
Ontology highlight
ABSTRACT: Purpose
Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (168Ga)-labelled radiotracers. Alternatively, fluorine-18 (18F)-labelled PSMA tracers are available, such as 18F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. In this study we evaluate the lesion detection efficacy of 18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.Methods
A total of 248 consecutive patients were evaluated and underwent scanning with 18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120 min after injection of a median dose of 311 MBq 18F-DCFPyL.Results
In 214 out of 248 PET/CT scans (86.3%), at least one lesion suggestive of cancer recurrence was detected ('positive scan'). Scan positivity increased with higher PSA values: 17/29 scans (59%) with PSA values <0.5 ng/ml; 20/29 (69%) with PSA 0.5 to?<1.0 ng/ml; 35/41 (85%) with PSA 1.0 to?<2.0 ng/ml; 69/73 (95%) with PSA 2.0 to?<5.0 ng/ml; and 73/76 (96%) with PSA ?5.0 ng/ml. Interestingly, suspicious lesions outside the prostatic fossa were detected in 39-50% of patients with PSA <1.0 ng/ml after radical prostatectomy (i.e. candidates for salvage radiotherapy).Conclusion
18F-DCFPyL PET/CT offers early detection of lesions in patients with BCR, even at PSA levels <0.5 ng/ml. These results appear to be comparable to those reported for 68Ga-PSMA and 18F-PSMA-1007, with potentially increased detection efficacy compared to 68Ga-PSMA for patients with PSA <2.0.
SUBMITTER: Wondergem M
PROVIDER: S-EPMC6647179 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Publications
Early lesion detection with <sup>18</sup>F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.
European journal of nuclear medicine and molecular imaging 20190622 9
<h4>Purpose</h4>Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (<sup>168</sup>Ga)-labelled radiotracers. Alternatively, fluorine-18 (<sup>18</sup>F)-labelled PSMA tracers are available, such as <sup>18</sup>F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. In this study we evaluate the lesion detection efficacy of <sup>18</su ...[more]